Showing results (41-50 of 212) with videos related to

Sort By:
Pageof 22
Biomolecules|October 23, 2021
Mevalonate Kinase Deficiency and Squalene Synthase Inhibitor (TAK-475): The Balance to Extinguish the InflammationErika Rimondi, Erica Valencic, Alberto Tommasini, et al.
Investigational New Drugs|August 18, 2010
In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibodyGiorgio Zauli, Federica Corallini, Sonia Zorzet, et al.
Investigational New Drugs|September 10, 2010
Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenograftsPaola Secchiero, Federica Corallini, Barbara Zavan, et al.
Journal of Cellular Physiology|October 26, 2005
Involvement of TRAIL/TRAIL-receptors in human intestinal cell differentiationErika Rimondi, Paola Secchiero, Andrea Quaroni, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 27, 2007
MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathwayGiorgio Zauli, Erika Rimondi, Federica Corallini, et al.
Cytokine|June 1, 2013
The circulating levels of TRAIL are extremely low after delivery but rapidly recover in both mothers and newbornsGiorgio Zauli, Lorenzo Monasta, Liza Vecchi Brumatti, et al.
Investigational New Drugs|December 3, 2010
Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAILArianna Gonelli, Oriano Radillo, Sara Drioli, et al.
Clinical and Translational Science|May 7, 2010
MicroRNAs as new players in the genomic galaxy and disease puzzlesElisa Barbarotto, Paola Secchiero, Abhijit Dasgupta, et al.
The American Journal of Pathology|February 1, 2005
Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromesDiana Campioni, Paola Secchiero, Federica Corallini, et al.
Pageof 22